Application of ginsenoside Rh2 in preparation of medicines for preventing and treating inflammatory bowel diseases

A technology of inflammatory bowel disease and ginsenoside, which is applied in the field of biomedicine, can solve the problems of adverse reactions of flora disorder, affecting the treatment effect of patients, and limiting the clinical efficacy of inflammatory bowel disease, etc.

Inactive Publication Date: 2018-05-04
CHINA PHARM UNIV
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term use of such drugs will lead to adverse reactions of flora disturbance, which seriously affects the treatment effect of patients, thus often limiting the clinical efficacy of inflammatory bowel disease
At present, there is no report about the use of ginsenoside Rh2 in the preparation of drugs for the prevention and treatment of inflammatory bowel disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside Rh2 in preparation of medicines for preventing and treating inflammatory bowel diseases
  • Application of ginsenoside Rh2 in preparation of medicines for preventing and treating inflammatory bowel diseases
  • Application of ginsenoside Rh2 in preparation of medicines for preventing and treating inflammatory bowel diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Dextran Sulfate Sodium Enteritis Mice Modeling: After C57 / B6 mice were raised in the animal room for 7 days, 2% dextran sulfate sodium solution was given in the drinking water of the mice for 5 days, and the mice were replaced every 2 days. The prepared dextran sodium sulfate solution, and then return to normal drinking water for 5 days, this 10 days is a cycle, lasting 2 cycles, and then give the dextran sodium sulfate solution with a mass concentration of 2% for 7 days, changing every 2 days Reconstituted dextran sodium sulfate solution, and then resume normal drinking water for 5 days, this 12 days is a cycle, lasting 2 cycles. For a total of 4 cycles of feeding dextran sodium sulfate solution, the mice were weighed daily. Then the mice were randomly divided into four groups: blank group, model group, ginsenoside Rh2 group, sulfasalazine SASP group. From the 6th day after modeling, the drug administration intervention started: Rh2 group was given 50 mg / kg ginsenosid...

Embodiment 2

[0066] For details on the modeling method of dextran sodium sulfate enteritis mice, the method of feeding the mice and the method of killing the mice, see Example 1. Colon tissue was dissected in a clean bench, and the length of the colon was measured and photographed. The distal 0.5 cm of the colon was taken and washed with normal saline, fixed with 4% paraformaldehyde for 24 hours, then dehydrated, embedded in paraffin, sliced, and stained with HE. Dehydration, embedding in paraffin, slicing and HE staining were performed using conventional methods. Yes, see pathological section results figure 2 .

[0067] Histological scoring: Observe under a microscope and develop histological scoring criteria according to the literature:

[0068] ① Lesion range: none, 0 points; 1-25%, 1 point; 26-50%, 2 points; 51-75%, 3 points; 76-100%, 4 points;

[0069] ② Depth of lesion: none, 0 points; upper mucosa, 1 point; lamina propria, 2 points; mucosa and submucosa, 3 points; muscularis and...

Embodiment 3

[0077] Colon tissue inflammatory factor gene expression:

[0078] For details on the modeling method of dextran sodium sulfate mice, the method of feeding the mice and the method of killing the mice, see Example 1. The colon tissue was dissected, rinsed, 0.5 mg was weighed, an appropriate amount of Trizol was added, RNA was extracted according to the Takara total RNA extraction kit, and RNA was quantified. The mRNA was reverse transcribed into cDNA according to the instructions of the RT-PCR kit. PCR experiments were performed according to the instructions of the ThermalCycler DiceTM Real TimeSystem (TakaRa Code: TP800), and the results are shown in image 3 . The quantitative PCR reaction conditions were:

[0079] Stage1: Pre-denaturation: 95℃, 30sec;

[0080] Stage2: PCR reaction: 95℃, 10sec; 60℃, 30sec; 72℃, 30sec; 40cycles;

[0081] Stage3: Melting curve analysis: 95°C, 15sec; 70°C, 15sec.

[0082] according to image 3It can be concluded that (A) is the relative ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of ginsenoside Rh2 in preparation of medicines for preventing and treating inflammatory bowel diseases. According to the application in the invention, the ginsenoside Rh2 is capable of increasing the content of beneficial microorganisms in the intestinal tract and reducing the content of harmful microbes in the intestinal tract by regulating microbial equilibriumin the intestinal tract, and intestinal flora disturbance is avoided, so that the content of inflammatory factors such as TNF-alpha, IL-6 and IL-1beta in the colon is reduced. Therefore, the inflammatory bowel diseases can be effectively treated.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of ginsenoside Rh2 in the preparation of medicines for preventing and treating inflammatory bowel disease. Background technique [0002] Inflammatory bowel disease (IBD) is a chronic, idiopathic inflammatory bowel disease, mainly involving the ileum, colon, rectum and other lesions. The clinical manifestations are recurrent intestinal ulcers and inflammation. There is an increasing trend year by year. The etiology and pathogenesis of inflammatory bowel disease are complex, and the current research is still unclear. Among them, genetic factors, living environment, dietary habits, and immune infections may all be possible causes of inflammatory bowel disease. At present, the main clinical drugs for the prevention and treatment of inflammatory bowel disease are 5-aminosalicylic acids, glucocorticoids and immunomodulators. However, long-term use of these drugs w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P1/00A61P1/14A61P29/00
CPCA61K31/704A61P1/00A61P1/14A61P29/00Y02A50/30
Inventor 张经纬金孝亮王广基周芳程琛康安
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap